Immunoscore provides prognostic information in low (T1-3N1) and high risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)
   Google Scholar   
Citation:
J Clin Oncol vol 36 (suppl 4S) asbstr 614
Meeting Instance:
ASCO GI 2018
Year:
2018
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2802   3167   3847  
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Eli Lilly and Company, Pfizer, Bristol-Myers Squibb  
Grants:
U10CA180821, U10CA180882, U10CA180820, U10CA180863, U10CA180888, CCSRI 021039  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: